B cell biology: An overview topical collection on basic and applied science

Current Allergy and Asthma Reports

Volumn 14, Issue 5, 2014, Pages

  Eibel, Hermann ^a   Kraus, Helene ^a   Sic, Heiko ^a,b   Kienzler, Anne Kathrin ^c   Rizzi, Marta ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

B cell; Biology; GC reaction; Memory B cells; Plasma cells; T cells

Indexed keywords

B LYMPHOCYTE RECEPTOR; DNA; ANTIGEN; TRANSCRIPTION FACTOR;

ALLERGY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL COMPARTMENTALIZATION; CELL DIVISION; CELL MIGRATION; CELL TYPE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MITOTIC RECOMBINATION; NONHUMAN; SOMATIC MUTATION; ANIMAL; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; REVIEW;

ANIMALS; ANTIGENS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; IMMUNOLOGIC MEMORY; TRANSCRIPTION FACTORS;

EID: 84898807636     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-014-0434-8     Document Type: Article

References (177)

1. Ghia P, ten Boekel E, Rolink AG, Melchers F. B-cell development: a comparison between mouse and man. Immunol Today. 1998;19:480-5.
2. Ferreiros-Vidal I et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood. 2013;121:1769-82.
3. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol. 2002;2:162-74.
4. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol. 2006;7:382-91.
5. Thompson EC et al. Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity. 2007;26:335-44.
6. Ma S et al. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010;30:4149-58.
7. Sun L et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1999;96:680-5.
8. Holmfeldt L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242-52. This extensive genomic profiling approach to ALL reports chromosomal alterations linked to Ras, Ikaros and TP53.
9. Molnar A, Georgopoulos K. The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins. Mol Cell Biol. 1994;14:8292-303.
10. Papathanasiou P et al. Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity. 2003;19:131-44.
11. Schjerven H et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol. 2013;14:1073-83. The authors demonstrate distinct roles of individual Ikaros Zn-fingers in gene regulation.
12. Kim J et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity. 1999;10:345-55.
13. Zhang J et al. Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. Nat Immunol. 2012;13:86-94. The paper describes how Ikaros regulates nucleosome remodeling and histone modification.
14. Turner Jr CA, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin- secreting cells. Cell. 1994;77:297-306.
15. Ye BH et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-70.
16. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635-9.
17. Kosan C et al. Transcription factor miz-1 is required to regulate interleukin-7 receptor signaling at early commitment stages of B cell differentiation. Immunity. 2010;33:917-28.
18. Moroy T, Khandanpour C. Growth factor independence 1 (Gfi1) as a regulator of lymphocyte development and activation. Semin Immunol. 2011;23:368-78.
19. de Almeida Ribeiro C et al. The DNA-binding protein CTCF limits proximal Vkappa recombination and restricts kappa enhancer interactions to the immunoglobulin kappa light chain locus. Immunity. 2011;35:501-13.
20. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26:715-25.
21. Singh H, Medina KL, Pongubala JM. Contingent gene regulatory networks and B cell fate specification. Proc Natl Acad Sci U S A. 2005;102:4949-53.
22. Nechanitzky R et al. Transcription factor EBF1 is essential for the maintenance of B cell identity and prevention of alternative fates in committed cells. Nat Immunol. 2013;14:867-75. The paper shows that EBF1 and Pax5 induce lineage commitment by repressing alternative cell fates.
23. Borghesi L et al. E47 is required for V(D)J recombinase activity in common lymphoid progenitors. J Exp Med. 2005;202:1669-77.
24. Lin H, Grosschedl R. Failure of B-cell differentiation in mice lacking the transcription factor EBF. Nature. 1995;376:263-7.
25. Vallespinos M et al. B Lymphocyte commitment program is driven by the proto-oncogene c-Myc. J Immunol. 2011;186:6726-36.
26. Seo W, Ikawa T, Kawamoto H, Taniuchi I. Runx1-Cbfbeta facilitates early B lymphocyte development by regulating expression of Ebf1. J Exp Med. 2012;209:1255-62.
27. Lin YC et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol. 2010;11:635-43.
28. Zandi S et al. EBF1 is essential for B-lineage priming and establishment of a transcription factor network in common lymphoid progenitors. J Immunol. 2008;181:3364-72.
29. Welinder E, Ahsberg J, Sigvardsson M. B-lymphocyte commitment: identifying the point of no return. Semin Immunol. 2011;23:335-40.
30. Dengler HS et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9:1388-98.
31. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 1999;401:556-62.
32. Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol. 2001;20:65-82.
33. Delogu A et al. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006;24:269-81.
34. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8:463-70.
35. Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity. 2002;17:781-93.
36. Sanz E, Alvarez-Mon M, Martinez AC, de la Hera A. Human cord blood CD34+Pax-5+ B-cell progenitors: single-cell analyses of their gene expression profiles. Blood. 2003;101:3424-30.
37. Reynaud D, Lefort N, Manie E, Coulombel L, Levy Y. In vitro identification of human pro-B cells that give rise to macrophages, natural killer cells, and T cells. Blood. 2003;101:4313-21.
38. van Zelm MC et al. Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol. 2005;175:5912-22.
39. Puck JM et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet. 1993;2:1099-104.
40. Prieyl JA, LeBien TW. Interleukin 7 independent development of human B cells. Proc Natl Acad Sci U S A. 1996;93:10348-53.
41. Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20:394-7.
42. Campana D, Farrant J, Inamdar N, Webster AD, Janossy G. Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. J Immunol. 1990;145:1675-80.
43. Tsukada S et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279-90.
44. Minegishi Y et al. An essential role for BLNK in human B cell development. Science. 1999;286:1954-7.
45. Mansur A, Therattil J, Young RM, Frieri M. An atypical case of hypogammaglobulinemia. Ann Allergy Asthma Immunol. 2000;84:583-6.
46. Goldman JP et al. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol. 1998;103:335-42.
47. van der Loo JC et al. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood. 1998;92:2556-70.
48. Peled A et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845-8.
49. Ueda T et al. Hematopoietic repopulating ability of cord blood CD34(+) cells in NOD/Shi-scid mice. Stem Cells. 2000;18:204-13.
50. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A. 2002;99:413-8.
51. Ito M et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175-82.
52. Traggiai E et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304:104-7.
53. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol. 2005;79:13797-9.
54. Gorantla S et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol. 2007;81:2700-12.
55. Yu CI et al. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood. 2008;112:3671-8.
56. Banerjee P et al. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood. 2010;115:2640-8.
57. Rathinam C et al. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood. 2011;118:3119-28.
58. Hu Z, Yang YG. Full reconstitution of human platelets in humanized mice after macrophage depletion. Blood. 2012;120:1713-6.
59. Tanaka S et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol. 2012;188:6145-55.
60. Kraus H et al. A feeder free differentiation system identifies autonomously proliferating B cell precursors in human bone marrow. J Immunol. 2014;192(3):1044-54. This paper reports a feeder cell-free differentiation system for human B cells and autonomous proliferation of human pro-B and pre-B cells. The paper reports autonomous development and proliferation of human B cell precursors.
61. Rawlings DJ, Quan SG, Kato RM, Witte ON. Long-term culture system for selective growth of human B-cell progenitors. Proc Natl Acad Sci U S A. 1995;92:1570-4.
62. Fluckiger AC et al. In vitro reconstitution of human B-cell ontogeny: from CD34(+) multipotent progenitors to Ig-secreting cells. Blood. 1998;92:4509-20.
63. Kurosaka D, LeBien TW, Pribyl JA. Comparative studies of different stromal cell microenvironments in support of human B-cell development. Exp Hematol. 1999;27:1271-81.
64. La Motte-Mohs RN, Herer E, Zuniga-Pflucker JC. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood. 2005;105:1431-9.
65. Taguchi T et al. Interleukin-7 contributes to human pro-B-cell development in a mouse stromal cell-dependent culture system. Exp Hematol. 2007;35:1398-407.
66. Ichii M et al. Regulation of human B lymphopoiesis by the transforming growth factor-beta superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Exp Hematol. 2008;36:587-97.
67. Awong G et al. Human proT-cells generated in vitro facilitate hematopoietic stem cell-derived T-lymphopoiesis in vivo and restore thymic architecture. Blood. 2013;122:4210-9.
68. Wardemann H et al. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374-7.
69. Melamed D, Nemazee D. Self-antigen does not accelerate immature B cell apoptosis, but stimulates receptor editing as a consequence of developmental arrest. Proc Natl Acad Sci U S A. 1997;94:9267-72.
70. Pelanda R et al. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity. 1997;7:765-75.
71. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 1989;337:562-6. A seminal in vivo model to study clonal deletion of autoreactive B cells.
72. Brombacher F, Kohler G, Eibel H. B cell tolerance in mice transgenic for anti-CD8 immunoglobulin mu chain. J Exp Med. 1991;174:1335-46.
73. Erikson J et al. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature. 1991;349:331-4.
74. Hartley SB et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991;353:765-9.
75. Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature. 2012;489:160-4. A very elegant expermental model demonstrating that all peripheral B cells bind autoantigens although with different avidities.
76. Nemazee D, Hogquist KA. Antigen receptor selection by editing or downregulation of V(D)J recombination. Curr Opin Immunol. 2003;15:182-9.
77. Hartley SB et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 1993;72:325-35.
78. Fields ML, Erikson J. The regulation of lupus-associated autoantibodies: immunoglobulin transgenic models. Curr Opin Immunol. 2003;15:709-17.
79. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231-64.
80. Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110:228-32.
81. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3:958-65.
82. Zubair A, Frieri M. NF-kappaB and systemic lupus erythematosus: examining the link. J Nephrol. 2013;26:953-9.
83. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med. 2006;203:2551-62.
84. Thompson JS et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-11.
85. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol. 2004;173:2245-52.
86. Warnatz K et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009;106:13945-50.
87. Pieper K, et al. A common SNP impairs B cell activating factor receptor's multimerization, contributing to common variable immunodeficiency. J Allergy Clin Immunol. 2014. doi: 10.1016/j.jaci.2013.11.021.
88. Greil J et al. Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J Allergy Clin Immunol. 2013;131:1376-83. e1373.
89. Stepensky P et al. Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. J Allergy Clin Immunol. 2013;131:477-85. The paper underlines the strict dependece of human B cell development on NF-kappaB signaling.
90. Schweighoffer E et al. The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway. Immunity. 2013. The authors show that BAFFR-induced signals crossfeed into the BCR pathway and may represent "tonic" BCR signaling.
91. Yu X et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455:532-6.
92. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247:52-63.
93. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429-57.
94. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073-83.
95. Liu YJ et al. Mechanism of antigen-driven selection in germinal centres. Nature. 1989;342:929-31.
96. Liu YJ, Zhang J, Lane PJ, Chan EY, MacLennan IC. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol. 1991;21:2951-62.
97. Allen CD, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science. 2007;315:528-31.
98. Muramatsu M et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-63.
99. Revy P et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565-75.
100. Phan TG, Green JA, Gray EE, Xu Y, Cyster JG. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol. 2009;10:786-93.
101. Okada T et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol. 2005;3:e150.
102. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature. 2009;460:1122-6.
103. Hannedouche S et al. Oxysterols direct immune cell migration via EBI2. Nature. 2011;475:524-7.
104. Yi T et al. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity. 2012;37:535-48.
105. Kelly LM, Pereira JP, Yi T, Xu Y, Cyster JG. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and nonlymphoid tissues. J Immunol. 2011;187:3026-32.
106. Bannard O et al. Germinal center centroblasts transition to a centrocyte phenotype according to a timed program and depend on the dark zone for effective selection. Immunity. 2013;39:912-24. The paper shows how shuttling between dark and light zone regulates GC B cell proliferation, affinity maturation and memory vs. plasma cell development.
107. Wang X et al. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. J Exp Med. 2011;208:2497-510.
108. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11:403-15.
109. Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J Off Publ Fed Am Soc Exp Biol. 2007;21:1202-9.
110. Yatomi Y et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 2000;96:3431-8.
111. Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta. 2008;1781:477-82.
112. Venkataraman K et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102:669-76.
113. Pappu R et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295-8.
114. Schwab SR et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309:1735-9.
115. Matloubian M et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-60.
116. Sic H., et al. S1P-receptors control B cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia and multiple sclerosis. J Allergy Clin Immunol. 2014 in press. The first comprehenisve analysis of S1P-receptor expression and signaling in human B cells.
117. Green JA, Cyster JG. S1PR2 links germinal center confinement and growth regulation. Immunol Rev. 2012;247:36-51.
118. MacLennan IC. Germinal centers. Annu Rev Immunol. 1994;12:117-39.
119. Casamayor-Palleja M, Feuillard J, Ball J, Drew M, MacLennan IC. Centrocytes rapidly adopt a memory B cell phenotype on co-culture with autologous germinal centre T cell-enriched preparations. Int Immunol. 1996;8:737-44.
120. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature. 2001;411:489-94.
121. Schwickert TA et al. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med. 2011;208:1243-52.
122. Depoil D et al. Immunological synapses are versatile structures enabling selective T cell polarization. Immunity. 2005;22:185-94.
123. Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity. 2001;14:181-92.
124. Verbeke CS, Wenthe U, Zentgraf H. Fas ligand expression in the germinal centre. J Pathol. 1999;189:155-60.
125. Phan TG et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med. 2006;203:2419-24.
126. Thiel J et al. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol. 2012;129:801-10. e806.
127. van Zelm MC et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354:1901-12.
128. van Zelm MC et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010;120:1265-74.
129. Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol. 2003;170:686-94.
130. Wang LC et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 1998;12:2392-402.
131. Hymowitz SG et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem. 2005;280:7218-27.
132. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307:269-73.
133. Kienzler AK, Rizzi M, Reith M, Nutt SL, Eibel H. Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. J Allergy Clin Immunol. 2013;131:1695-9.
134. Yamaguchi T et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010;24:455-69.
135. Matthias P, Rolink AG. Transcriptional networks in developing and mature B cells. Nat Rev Immunol. 2005;5:497-508.
136. O'Riordan M, Grosschedl R. Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity. 1999;11:21-31.
137. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity. 2001;14:779-90.
138. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997;276:596-9.
139. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000;165:5462-71.
140. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002;22:4771-80.
141. Shaffer AL et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51-62.
142. Shapiro-Shelef M et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003;19:607-20.
143. Kallies A et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med. 2004;200:967-77.
144. Shaffer AL et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity. 2004;21:81-93.
145. Klein U et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7:773-82.
146. Kallies A et al. Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity. 2007;26:555-66.
147. Cattoretti G et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45-53.
148. Allman D et al. BCL-6 expression during B-cell activation. Blood. 1996;87:5257-68.
149. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276:589-92.
150. Basso K et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115:975-84.
151. Tunyaplin C et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173:1158-65.
152. Shaffer AL et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199-212.
153. Abecasis GR et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56-65. The report of the 1,000 genome project.
154. Saito M et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2009;106:11294-9.
155. Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med. 2005;202:1471-6.
156. Reimold AM et al. Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med. 1996;183:393-401.
157. Iwakoshi NN et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4:321-9.
158. Todd DJ et al. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med. 2009;206:2151-9.
159. Mittrucker HW et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540-3.
160. Sciammas R et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225-36.
161. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol. 1994;153:4357-66.
162. Han S et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol. 1995;155:556-67.
163. Basso K et al. Tracking CD40 signaling during germinal center development. Blood. 2004;104:4088-96.
164. Saito M et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer cell. 2007;12:280-92.
165. Ferrari S et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98:12614-9.
166. Jain A et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol. 2001;2:223-8.
167. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol. 2006;177:5236-47.
168. Ding BB, Bi E, Chen H, Yu JJ, Ye BH. IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J Immunol. 2013;190:1827-36.
169. Ozaki K et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173:5361-71.
170. Pene J et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol. 2004;172:5154-7.
171. Kotlarz D et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med. 2013;210:433-43. The paper shows the role of IL-21R signaling in immune responses of B, T and NK cells.
172. Scheeren FA et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol. 2005;6:303-13.
173. Diehl SA et al. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol. 2008;180:4805-15.
174. Avery DT et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207:155-71.
175. Holland SM et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608-19.
176. Minegishi Y et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058-62.
177. Hsu AP et al. Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol. 2013;131:1586-93.